

Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)

NCT06297993

Status	RECRUITING
Sponsor	PSC Partners Seeking a Cure
Enrollment	2,000 participants

Key Eligibility Criteria

Inclusion (2)

- Adult patients between 18 and 75 years of age (inclusive) who can comprehend instructions, follow the study procedures and are willing to sign an Informed Consent Form (ICF).
- Confirmed clinical diagnosis of large duct PSC.

Exclusion (22)

- Clinically significant acute or chronic liver disease of an etiology other than PSC (including but not limited to metabolic-dysfunction associated steatohepatitis (MASH), PBC, HCV, HBV, or alcoholic hepatitis, Wilson's disease, alpha-1 antitrypsin deficiency, acute or chronic drug-induced liver injury)
- Patients with PSC and elements of AIH overlap are allowed to enroll
- Patients with metabolic dysfunction associated steatotic liver disease (MASLD) or benign steatosis are allowed to enroll
- Small-Duct PSC.
- Clinically diagnosed secondary or IgG4-related sclerosing cholangitis.

... and 17 more (see full listing online)

Locations (16 total)

UC Davis, Sacramento, California, United States
California Pacific Medical Center, San Francisco, California, United States
University of California, San Francisco, San Francisco, California, United States
... and 13 more locations